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ABSTRACT

Albuterol sulfate is a short-acting selective Beta 2 Adrenergic agonist. It is used to treat
and prevent bronchospasm associated with asthma, bronchitis, and other breathing disorders. It is
known to show extensive first pass metabolism and it requires frequent dosing which makes it
difficult for patients to comply. To avoid these problems, transdermal route of delivery of
Salbutamol was explored. Traditional methods of preparation of transdermal drug delivery systems
involve the use of solvents and have multiple processing steps. To avoid the usage of solvents and
decrease the processing steps, HME Coupled FDM 3D printing can be used. Different polymers
such as Polyox WSR N-80, Eudragit RSPO, Kollidon VA64, Parteck MXP Polyvinyl Alcohol,
Kollidon 12PF, Polyox WSR 301, Affinisol 100 LV were used in combination with the drug to
extrude filaments with 11mm Twin Screw Extruder and then printed into patches with Prusa ik
MK3 FDM 3D printer. The patches were characterized for their thermal behaviour with
Differential Scanning Calorimetry (DSC), for drug content, weight variation, thickness, folding
endurance, patch burst strength with Texture Analyser (TA), moisture content, in-vitro drug
release in Vertical Franz Diffusion cells. Patches with drug release of 99.8± 0.2 (mean± SD) at 24
hours were formulated.
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CHAPTER Ⅰ. INTRODUCTION
Asthma is a chronic inflammatory disease of the respiratory system, characterized by hyper
responsiveness of tracheobronchial smooth muscles to various stimuli. Along with narrowing of
air tubes, it is often accompanied by increased mucus secretion, mucus plugging and mucosal
edema.
It is a long-term condition and it plagues both adults and children. There are common triggers
involved in the clinical expression of asthma. These can vary from person to person. Some of them
include, dust, smoke, viral infections, fumes, weather changes, pollen, animal fur/feathers, strong
perfumes etc.
According to WHO, asthma is often under-diagnosed and under-treated, in low and middle income
countries. People with untreated asthma face challenges like sleep disturbances, tiredness during
the day and poor concentration decreasing the quality of life. [14][15][16].
Albuterol sulfate is a short-acting selective Beta 2 Adrenergic agonist. It is used to treat and prevent
bronchospasm associated with asthma, bronchitis, and other breathing disorders. Albuterol sulfate
has higher specificity for pulmonary beta receptors in comparison to Beta 1-adrenergic receptors.
Albuterol sulfate is one of the most commonly prescribed drugs for asthma. Albuterol sulfate is
available in the following dosage forms and strengths: Aerosol metered-dose albuterol inhaler (90
mcg (base)/ actuation, equivalent to 108 mcg albuterol sulfate), Powder metered-dose albuterol
inhaler (90 mcg (base)/actuation, equivalent to 108 mcg albuterol sulfate), Tablet- 2 mg, 4 mg,
Tablet (extended release)- 4 mg, 8 mg, Nebulizer solution- 0.083%, 0.5%, 1.25 mg/ 3 ml, 0.63 mg/
3 ml, Syrup- 2 mg/5 ml. The dosing considerations for asthma maintenance- should be given as
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follows: Nebulizer solution: 2.5 mg 2/3 times / day and 1.25-5 mg every 4-8 hours as needed for
quick relief, Aerosol metered-dose inhaler: 180 mcg (2 puffs) inhaled orally every 4-6 hours, not
exceeding 12 inhalations/ 24 hours, Powder metered-dose inhaler: 180 mcg (2 puffs) inhaled orally
every 4-6 hours, not to exceed 12 inhalations/ 24 hours, one inhalation (90 mcg) every 4 hours
maybe sufficient in some patients, Tablet and syrup 2-4 mg orally every 6-8 hours: not to exceed
32 mg/day, extended release: 8 mg orally every 12 hours not to exceed 32 mg/day. Albuterol
sulfate undergoes extensive first-pass metabolism. Systemic bioavailability is 50%. It requires
frequent administration by the oral route. The strengths available for the inhalation route requires
dosing every 4-6 hours for relief. More frequent administration is not recommended. [41] In order
for the drug to be bioavailable, proper inhalation technique is required which varies every time
from patient to patient. The performance can differ based on the type of device. [42]
Transdermal drug delivery offers advantages compared to oral, injectable and inhaler options, such
as:
•

Improved systemic bioavailability due to avoidance of first pass metabolism by the liver
and digestive system (comparison with oral route).

•

The controlled constant drug delivery profile [43]

•

Frequency of dosing can be decreased, longer duration of action with single application
which increases patient compliance (comparison with oral and inhalation route).

•

Undesirable side effects can be reversed just by removing the patch (comparison with
injectable route).

Section 1.1 Transdermal Drug Delivery System
TDDS offers effective drug delivery, which is painless and easy to use. A transdermal patch
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involves the application of the formulation onto intact and healthy skin where the drug penetrates
through several layers of skin into the systemic circulation. The patch consists of components such
as, a liner (protection to the patch in storage), drug reservoir (which consists of the drug), release
membrane, adhesive and clear backing (to protect the patch from outside contamination). The drug
can be in a single layer/ multi-layer incorporated into adhesive, it can be separate as a reservoir or
the drug can be in a semisolid matrix. There are several studies in which transdermal patches of
Albuterol sulfate were attempted to evade the first-pass metabolism and avoid continuous drug
administration Albuterol sulfate can be safely delivered through the skin with the help of TDDS.
[27] – [30], [41], [44].

FIGURE A

FIGURE B

FIGURE 1.1 Figure A- Matrix type transdermal system, Figure B- Reservoir type transdermal
system- Source FDA Transdermal and Topical Delivery Systems DRAFT GUIDANCE. [32].
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Section 1.2 Physiology of Skin:
The human skin is the second largest organ that is the outermost covering of the body. The skin
has several layers histologically divided into the epidermis, the dermis, and the hypodermis.
The epidermis is waterproof and serves as a barrier to infection. There is a non-viable and viable
epidermis. The non-viable part of the epidermis is the stratum corneum. The viable epidermis is
made of several sublayers including stratum basale (basal cell layer), stratum spinosum (prickle
cell layer), stratum granulosum (granular cell layer), and stratum lucidum (clear layer).
The dermis has a rich supply of blood vessels, sebaceous glands, sweat glands, and hair follicles.
The dermis has sublayers such as the papillary layer, reticular layer.
The hypodermis or subcutis is an elastic layer and includes a large number of fat cells. The
thickness of this layer varies from body region to body region and person to person.
The main route of permeation of the drug is through the stratum corneum (horny layer), around its
cells called corneocytes. The corneocytes size depends upon the site of the body which regulates
the permeation. [30] [31]
Section 1.3 Routes of drug penetration through the skin:
The trans-epidermal pathway/route of drug penetration is divided into two types


The transcellular route, where the drug passes through the cytoplasm of corneocytes and
the lipid arrangement of the stratum corneum. Water-soluble molecules are largely
transported in this route.



The intercellular route, where the drug passes through endogenous lipid within the stratum
corneum.

A molecule must partition and diffuse through several lipid lamellae and keratinocytes which is
not very favorable for many drugs. In the case of transdermal patches, the absorption occurs
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through a slow process of diffusion driven concentration gradient, requiring for the drug to be kept
in continuous contact with the skin for a considerable time.[30] [31]

Section 1.4 Drug Profile and Pre-Formulation Parameters of Albuterol sulfate for
Transdermal route of delivery:


Albuterol sulfate



IUPAC Name: 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;sulfuric acid



Molecular Formula: C26H44N2O10S



Molecular weight : 576.7[33]



Log P : 0.11[41]

FIGURE 1.2 Structure of Albuterol and Albuterol sulfate Source Pubchem [33]
Section 1.5 Hot-Melt Extrusion coupled with FDM 3D printing:
For the preparation of transdermal patches hot melt extrusion coupled FDM 3D printing can be
explored because:
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•

Hot melt extrusion maybe used to disperse the drug in a given matrix at molecular level.

•

3D printing of the filaments can help with the personalization of the patch in terms of shape,
size, pattern etc.

•

It is a versatile, safe and user friendly technique with a wide range of commercial machines
with high to low budget ranges.

Mechanism of Hot Melt Extrusion:
HME is a continuous process where the drug is mixed with carriers in solid form, to which heat
and pressure is applied to melt or soften materials through an orifice to produce filaments of
uniform shape and density. The extruder is the main component of HME which has some basic
elements assembled like the extrusion barrel, rotating screws in the barrel with rotating screws, die
and motor. The extruder also contains heaters that provide heat for the melting or softening of
materials. The rotating screws can provide shear stress, intense mixing of the materials. The heat
and the mixing causes the materials to melt and the screws convey the material down the barrel.
This extruder is controlled through a central electrical control. Some of the processing parameters
that can be controlled are screw speed in revolutions per minute (RPM), feed rate, temperature
along the barrel and die and the vacuum level for devolatilization.
Mechanism of Fused Deposition Modelling:
In FDM 3D printing the drug loaded filaments are fed into the printer which are then melted and
softened and extruded out of the printer head onto the build plate as many layers each of which is
fused together. These layers cool down and solidify and other layers are added on top of it until
the printing is finished. [35] [36].
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Objective: The aim of this study was to prepare albuterol sulfate loaded transdermal patches by
HME coupled FDM 3D printing, to decrease dosing frequency and overcome the problem of first
pass metabolism.
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CHAPTER II MATERIALS AND METHODS
Section 2.1 MATERIALS AND INSTRUMENTS
Table 2.1: List of Materials
S.No Materials

Chemical name of the Details
polymers

1

Salbutamol

sulfate

Sheerji Pharma, India.

(albuterol sulfate)
2

3

PolyoxWSR

N-80

(PEO Poly(ethylene

oxide) Colorcon, USA.

WSR N-80)

mw. 200,000.

Kollidon VA64

Copovidone, VP/VAc BASF, Germany.
copolymer 60/40

4

ParteckMXP

Poly vinyl alcohol

5

Eudragit RSPO

Poly(ethyl acrylate-co- Evonik
methyl

Millipore Sigma, Germany.
Nutrition

methacrylate- Germany

cotrimethylammonioethyl
methacrylate chloride)
1:2:0.1
6

Kollidon 12PF

Povidon(e),
polyvidone,

8

BASF, Germany
soluble

and

care,

polyvinylpyrrolidone,
PVP
7

Polyox WSR 301 (PEO Poly (ethylene oxide) Dupont, Germany.
WSR 301)

mw 4,000,000.

8

Affinisol 100LV

HPMC HME

9

Methanol

10

PBS10X Solution

Dupont, Germany.
Fisher Scientific, USA.

Phosphate buffer saline VWR, Germany

Instruments:
For Hot Melt Extrusion: 11 mm Twin Screw Extruder, Thermo Scientific, USA.
For FDM 3D printing: Prusa i3 MK3 Printer, Czech Republic.
For DSC: TA Instruments, USA.
For Three point bend test: Texture Analyzer TAXT2i with TA-92N Three point bend rig, with a
testing knife, Stable Microsystems/Texture Technologies Corporation, UK.
For spectrophotometric analysis: Thermo Scientific Genesys UV Visible Spectrophotometer,
USA.
For Burst Strength: Texture Analyzer TA XT2i with TA 8 Ball Probe and TA-108s5
Small Film Extensibility Rig, Stable Microsystems/Texture Technologies Corporation, UK.
For In vitro Drug Release: Vertical Franz Diffusion Cells with a volume of 5 ml and contact area
0.64 cm Logan Instruments Corp, USA.
2

Section 2.2 METHODS: [27]-[29] [38]-[40]
2.2.1 Preparation of hot melt extrudates:
The polymers and drug of batch size 30 g were hand mixed and sieved through 30 mesh to get a
9

uniform mixture without lumps. The drug polymer mixture was placed in a container (filled to 3/4

th

of the container) and placed in a laboratory size V- Blender for 15-20 minutes (based on the
polymer flowability) to get a uniform mixture. The blend was extruded through an 11 mm Twin
Screw Extruder (Thermo Scientific, USA.) with a 1.5 mm diameter die.
Table 2.2 Composition of Formulations
Formulation
AFFINISOL 100LV +SBT
AFFINISOL100LV+SBT
PEO WSR N-80+SBT
KOLLIDON VA64+SBT
EUDRAGIT RSPO+SBT
KOLLIDON 12PF +SBT
PEO WSR 301+SBT
PVA+SBT
PEO WSR N-80+ KOLLIDON VA64+SBT
PEO WSR N-80+ KOLLIDON VA64+SBT
PEO WSR N-80+ EUDRAGIT RSPO+SBT
PEO WSR N-80+ EUDRAGIT RSPO+SBT
PEO WSR N80+ EUDRAGIT RSPO+ SBT
PEO WSR N-80+EUDRAGITRSPO+SBT
KOLLIDON12PF+PEO WSR N-80 +SBT

F1
F2
F3
F4
F5
F6
F7
F8
F9
F10
F11
F12
F13
F14
F15

Ratio
95:5
90:10
95:5
95:5
90:10
90:10
90:10
90:10
80:10:10
60:30:10
85:5:10
80:10:10
60:30:10
30:60:10
60:30:10

FIGURE 2.1 Screw Configuration used to prepare the filaments Source European journal of
pharmaceutical sciences [37]

.
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2.2.2 FDM 3D Printing of the hot melt extrudates:
The patch was designed in TinkerCAD (USA) and the filaments were printed in a Prusa i3 MK3
printer (Czech Republic), with the Ultimaker Cura (Netherlands) software. The filaments which
were of thickness ranging from 1.5-1.7 mm were loaded into the printer and printed with the
parameters listed below.
Table 2.3 Parameters set in the FDM 3D Printer.
Parameters
Patch shape

Circular

Dimensions

20 x 20 mm diameter, thickness 0.2 mm.

Profile

Fine 0.2 mm

Layer height

0.1 mm or 0.2 mm.

Wall thickness

0.8 mm.

Wall line count

2

Top bottom layers and thickness

1-2 layers, 0.1-0.2mm

Infill Density

100.0%

Infill Pattern

Zig Zag

Printing temperature

180.0 ˚C

Build Plate temperature

50.0-60 ˚C

Print speed

60.0 mm/S.

The dimensions were chosen to achieve a patch weight of 50mg with 5mg drug load. (It is reported
that a 5 mg drug load would help with the flux rate to obtain steady state serum concentration
enough to improve the symptoms of asthma.) [41] [46].
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Section 2.3 EVALUATION METHODS: [27]-[29] [38]-[40]
The extruded filaments were tested for printability with three point bend test. The prepared patches
were evaluated for thermal characterization (DSC), Drug content, Weight variation, Thickness,
Folding endurance, Patch Burst strength, Moisture Content, In-vitro drug release.
2.3.1 Thermal Characterization by differential scanning calorimetry (DSC):
The characteristic peaks of the drug and the polymer from the extruded filaments and patches and
the polymer-drug blend (physical mixture) is measured using Differential Scanning Calorimetry
(TA Instruments, USA). The materials were placed in aluminum pans and heated to 230 ˚C at a
rate of 10 ˚C/min and the thermograms were recorded.
2.3.2. Three Point Bend Test:
The strength of the filaments (required to print through the FDM 3D printer) was tested by Texture
Analyzer TAXT2i with TA-92N three point bend rig, with a testing knife, Stable
Microsystems/Texture Technologies Corporation, UK. Six filaments of length 6 cm were placed
individually on the testing rig and the testing knife was lowered until the filament broke. The
samples were acceptable if the time taken to break the filaments is more than 1 second.
2.3.3 Percent drug content:
The percent drug content in the filaments and patches were determined by using UV-Visible
Spectrophotometry (Thermo Scientific Genesys UV Visible Spectrophotometer, USA). The
filaments and patches were weighed and completely dissolved (no visible particles or
agglomerations) in 50 ml of water: methanol (1:1) mixture for 24 hours and sonicated for two
hours. The solution was filtered through a 0.45 um filter. The mixture was appropriately diluted
(Dilution factor 100) and measured at 226 nm spectrophotometrically. A calibration curve was
constructed with 0.5, 1, 2.5, 5, 10, 25, 50, 100 ug/ml dilutions made from 1000 ug/ml prior to this
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with the drug dissolved in water:methanol (1:1).
PERCENT DRUG CONTENT = Amount of Drug*100/Dose

2.3.4 Weight variation:
Six patches were tested for weight variation and the mean standard deviation was reported.
2.3.5 Thickness:
Six patches were tested for variation in thickness by placing them in between glass slides and the
thickness of the setup was measured with Vernier calipers and the mean standard deviation.
2.3.6 Folding endurance:
Six patches were tested for their strength and endurance to fold by repeatedly folding the patches
in the same place until the patch was completely broken into pieces.
2.3.7 Patch burst strength:
The burst strength (kg/cm ) of a patch is the force required to break a patch, which is an indicator
2

of its strength. It was measured in the Texture analyzer Texture Analyzer TA XT2i with TA 8 Ball
Probe and TA-108s5 Small Film Extensibility Rig, (Stable Microsystems/Texture Technologies
Corporation, UK.), using a ball probe. The patch was placed in the rig and the test was performed.
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Table 2.4 Parameters set in the T.A.

Parameter
Mode

Measure force in compression.

Option

Return to start

Pre-test speed

2 mm/s

Test speed

1 mm/s

Post-test speed

10 mm/s

Target mode

Distance

Distance

5 mm

Trigger type

Auto

Trigger force

5g

Stop plot at

Target position

Tare mode

Auto

2.3.8 Percent moisture content:
Six patches were weighed and placed in a desiccator with AlCl3 Crystals for 24 hours and checked
for difference in weight.
Percent moisture content = [Initial weight-Final Weight/Initial weight]*100
2.3.9 In-vitro drug release:
In-vitro drug release of the patches was tested by using the Franz diffusion cell apparatus (Vertical
Franz Diffusion Cells with a volume of 5 ml and contact area 0.64 cm 2 Logan Instruments Corp,
USA). The cells were prepared by washing with methanol and water (1:1) mixture and set aside
to dry. The prepared patches were placed on the donor chamber and clamped down to the cell body
in which the receptor medium of Phosphate Buffer Saline 7.4 (5 ml) was maintained at 32±0.5 ˚C.
Samples were withdrawn from the sample port at 15 min, 30 min, 45 min, 60 min, 90 min, 120
14

min, 180 min, 240 min, 360 min, 480 min and 24 hours. The number of samples for each type of
patch was 3. The withdrawn samples were diluted appropriately with the PBS and measured in
UV Spectrophotometer at 226 nm. The membrane used was a Nylon membrane of pore size 0.22
um. The amount of drug release at each time point was calculated from the linear equation of a
calibration

curve

constructed

with

appropriate

dilutions

with

PBS.(i.e.,

1,2.5,5,10,25,50,100,200,500 ug/ml from 1000 ug/ml) The percent drug release was calculated
based on the starting amount of the drug.
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CHAPTER III RESULTS AND DISCUSSION
Table 3.1 Polymer Selection Criteria, Extrusion Conditions, Printability, Filament properties (by
visual observation), Patch Nature.

Formulation

Selection criteria for
polymers

Temperature and
extrusion
conditions.

Filament properties
Printability.

Patch
nature

Suitable for HME, Lower Tg,
extended release, no use of
plasticizer. [1] [2] [3]

Temp:
Zone 2: 25˚C
Zone 3-8: 150 ˚C
Die: 170 ˚C
Screw speed: 50-70
rpm.

Hard, No printability,
Time

-

F2

Same as above.

Temp:
Zone2 25˚C
Zone3-8 150˚C
Die 170˚C
Screw speed 50rpm

Hard, difficult to extrude.
No printability

-

F3

Film former, extended release,
transdermal application, low
Tg.[4] [10] [11]

Temp:
Zone 2:25 ˚C
Zone3-8 125˚C
Die 130˚C
Screw speed 50rpm

Soft, breakable,
Printable.

Breakable

Film former, extended release,
transdermal application [5] [6]

Temp:
Zone2 25˚C
Zone3-8 165˚C
Die 165˚C
Screw speed 20 rpm

No filaments could be
extruded, very sticky and
hard. No printability.

-

Transdermal application,
extended release[7] [8]

Temp:
Zone2 25 ˚C
Zone3-8 180˚C
Die 190˚C
Screw speed 30 rpm

Hard and brittle filaments,
No printability.

-

F1

F4

F5

16

F6

Transdermal application,
extended release[9] [5]

Temp:
Zone2 25 ˚C
Zone3-8 160 ˚C
Die 160˚C
Screw speed 50rpm

F7

Film former, extended release,
transdermal application, low
Tg.[4][11]

Temp:
Zone2 25˚C
Zone3-8 160 ˚C
Die 160˚C
Screw speed 50 rpm

Hard filaments,
Not printable.

-

F8

Film former, transdermal
applicationFilm former,
transdermal application[12] [13]

Temp:
Zone2 25 ˚C
Zone3-8 125 ˚C
Die 130˚C
Screw speed 20rpm

Flexible ,
Not printable.

-

F9

Combination for stronger
filaments/ films, extended
release.

Temp:
Zone2 25˚C
Zone3-8 125˚C
Die 125˚C
Screw Speed 50rpm

Flexible, Printable

Flexible

F10

Combination for Stronger
filaments/films, extended
release

Temp:
Zone2 25˚C
Zone3-8 125˚C
Die 125˚C
Screw speed 50rpm

Slightly hard,
Printable.

Breakable

F11

Combination for Stronger
filaments/films, extended
release

Temp:
Zone2 25 ˚C
Zone3-8 135˚C
Die 135˚C
Screw speed 50rpm

Soft filaments,
Printable.

Breakable

F12

Combination for stronger
filaments/films, extended
release.

Temp:
Zone2 25 ˚C
Zone3-8 135˚C
Die 135˚C
Screw speed 50rpm

Flexible, printable

Flexible

F13

Combination for stronger
filaments/films, extended
release.

Temp:
Zone2 25 ˚C
Zone3-8 135˚C
Die 135˚C
Screw speed 50rpm

Flexible, printable

Flexible
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Soft filaments
Not Printable

-

F14

Combination for Stronger
filaments/films, extended
release

Temp:
Zone2 25 ˚C
Zone3-8 180˚C
Die 190˚C
Screw speed 10rpm

Hard, Brittle, not printable

-

F15

Combination for Stronger
filaments/films, extended
release

Temp:
Zone2 25 ˚C
Zone3-8 135˚C
Die 135˚C
Screw speed 50rpm

Very soft and breakable,
not printable.

-

3.1 Breakdown of the extrusion and printing results:
Several polymers were screened for hot melt extrusion coupled with FDM 3D printing. The
combinations of different polymers and the ratio of the drug were selected based on the extrusion
temperature, flexibility of the filaments and later the printability of the filament. Hot Melt
Extrusion temperature was desired to be no more than 180 ˚C to avoid discoloration and softening
of the filaments as well as die swelling. The hardness, softness and brittleness described above
were visually observed.
The filaments needed to be flexible enough to be fed through the print head in the FDM 3D printer.
Temperature higher than 180 ˚C in the printing was causing clogging of the products (turning from
off-white to yellow colour) in the nozzle, which may be indicative of some level of degradation or
changes in the composition of the drug and the polymer. And it is undesirable for transdermal
applications to be unattractive in color as it will not be acceptable by the patients.
Three combinations that were successful in giving flexible patches for further testing were F9,
F12, F13. They are combinations of PEO WSR N-80, Eudragit RSPO and PEO WSR N-80,
Kollidon VA64. Increase in the concentrations of Eudragit RSPO or Kollidon VA64 caused the
filaments and patches to be brittle. The flexibility was also affected by the drug concentration, as
higher concentration of Salbutamol sulphate made the filaments soft, which were not suitable for
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printing. The major component in these three formulations is PEO WSR N-80, due to which the
filaments were flexible and printable enough. Pure PEO WSR N-80 and the drug combination gave
filaments that clogged up the printer nozzle due to its low degradation temperature, hence Kollidon
VA64 and Eudragit RSPO were chosen to give the filaments flexibility.
Polyox WSR N-80 (PEO WSR N-80):
PEO WSR N-80 is a synthetic polymer obtained by the catalyst of an ethylene oxide monomer.
PEO WSR N-80 has a molecular weight of 200 kDa. The polymer is known to show pronounced
degradation after 150 ˚C. It is semi crystalline and is flexible for choosing extrusion temperature
due to its glass transition, melting and decomposition temperatures. It has low toxicity in all routes,
no skin irritation was reported. It is used as a rate controlling polymer suitable for hotmelt extrusion
due to its thermoplastic nature along with good flow and low glass transition temperature. [4]

FIGURE 3.1 Example of a printed patch of F13.
3.2 Three point bend test:
Table 3.2 Three point bend test of the filaments that gave acceptable patches.

Formulation

Time in seconds (mean ± SD)

F9

1.5 ± 0.2

F12

1.9 ± 0.9

F13

1.3 ± 0.4
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The filaments were broken after 1 second, which was taken as an indicator that they were
flexible enough to be printed without breaking and clogging the nozzle of the printer.
3.2 Thermal Characterization (DSC thermograms):

FIGURE 3.2 DSC Thermogram of Albuterol sulfate
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FIGURE 3.3 DSC Thermogram of PEO WSR N-80
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FIGURE 3.4 DSC Thermogram of Kollidon VA64
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FIGURE 3.5 DSC Thermogram of Eudragit RSPO
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FIGURE 3.6 DSC Overlays of Drug, PEO, Physical Mixture, Filament and Patch of F9
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FIGURE 3.7 DSC Overlays of Drug, PEO N80, Physical Mixture, Filament and Patch of
F12
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FIGURE 3.8 DSC Overlays of Drug, PEO, Physical Mixture, Filament and Patch of F13
The characteristic peaks of the drug and the polymers were measured as shown in Figure 3.8 the
DSC Thermogram overlays of the Physical mixture, Filament and the Patch. Figure 3.8 showed
that the peak height of the drug decreased from the physical mixture to filament to patch indicating
the change of the physical state of the drug. These changes may be due to the hot melt extrusion
temperature and temperature used in 3D printing. The peaks of Kollidon VA 64 and Eudragit
RSPO were not sharp and well defined due to their semi-crystalline and amorphous natures
respectively (Figure 3.4 and 3.5).
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3.3 Percent drug content:

FIGURE 3.9 Calibration Curve for Albuterol sulfate Content in water : methanol (1:1)

Table 3.3 Albuterol sulfate Content of Filaments and Patches.

Formulation No.

% Drug Content Filament (mean±SD)

% Drug Content Patch
(mean±SD)

F9

98.5±0.57

94.3±0.71

F12

96.3±1.65

92.0±1.80

F13

98.9±0.25

97.9±0.36
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There is a slight decrease in the Albuterol sulfate content from filament to patch, which may be
due to the effect of temperature from 3D printing. The percent drug content was also reflective of
the type of mixing of the physical mixture, where over mixing (more than 15 minutes in the v
blender) caused significant differences between each sample (either patch or filament) which
may be due to the drug being denser than the polymers, causing the drug to separate from the
mixture.

3.4 Weight variation, thickness, folding endurance, percent moisture content:
Table 3.4 Weight variation, thickness, folding endurance, percent moisture content of patches.
Formulation

Weight variation

Thickness

Folding

Percent moisture

no.

(mg)

(mm)

Endurance (no.of

content (%)

(mean±sd)

(mean±sd)

folds)

(mean±sd)

50.7 ± 0.08

0.21

F9

± 78 - 80

0.32 ±0.21

± 66-68

0.24 ±0.21

± 170-175

0.24 ±0.21

0.002
F12

50.9 ± 1.11

0.22
0.010

F13

51.1 ± 0.05

0.23
0.010

All of the samples showed low standard deviation and less variability in between each sample for
weight variation, thickness and folding endurance. The difference in weight variation was
decreased by changing the parameters on the 3D printer suitably as well as avoiding overloading
the Print head which gave uniform thickness and less weight variation. In regards to moisture
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content, there was no significant difference in the weight of the patches after 24 hours, which
may be indicative of less moisture content in the patches.

3.5 Burst strength:
Table 3.5 Patch Burst Strength
Formulation Burst Strength kg/cm (mean±sd)
2

F9

4.55 ± 0.18

F12

4.51 ± 0.10

F13

3.88 ± 0.30

Increase in Eudragit RSPO ratio from 10 to 30 in the formulation decreased the patch burst
strength. Eudragit RSPO is known to make patches and films slightly more brittle.
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3.6 In-vitro drug release:

FIGURE 3.10 Calibration Curve for In-vitro Albuterol sulfate Release in PBS 7.4.

Cumulative Percent Release of the patches:
When the patches were placed in the donor cell, it was observed that the F 9 and F 12 patches
were rapidly dissolving in the receptor fluid. For F 9 the cumulative drug release was 99.22 ±
0.28 (mean ± SD) at 3 hours and saturation was seen and for F 12 the cumulative drug release
was 99.38 ± 0.16 (mean ± SD) at 6 hours, followed by saturation. But for the F 13 patches, the
cumulative drug release was 75.7 ± 1.5 % (mean ± SD) was at 8 hours and at 24 hours the
cumulative release was 99.8 ± 0.2 (mean ± SD). As Kollidon VA 64 is a rapid release polymer it
is showing faster release and increase in Eudragit RSPO ratio is increasing the delay in the
release of the drug from the formulation because it is a delayed release polymer.
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FIGURE 3.11 Comparison between release of F9, F12, F13.

CONCLUSION:
Several polymer-albuterol sulfate combinations have been screened for extrudability from HME
and for printability in FDM 3D Printing for the preparation of transdermal patches. The
combinations of PEO WSR N-80, Kollidon VA64 and PEO WSR N-80, Eudragit RSPO gave the
most flexible patches. Patches with the highest Eudragit RSPO concentration gave more of an
extended release profile whereas the patches with Kollidon VA64 gave faster release. The
patches with high Eudragit RSPO would be more suitable to fulfil the objective of preparing
extended release albuterol sulfate transdermal patches.
FUTURE STUDIES:
Patch adhesive preparation, compatibility studies.
Ex-vivo permeation studies to assess the permeability and the flux of albuterol sulfate from the
matrix, permeation enhancement strategy development.
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